Antiviral Activity of PLK1-Targeting siRNA Delivered by Lipid Nanoparticles in HBV-Infected Hepatocytes | Zendy

Adrien Foca | Zendy; Ammen P. Dhillon | Zendy; Thomas Lahlali | Zendy; Julie Lucifora | Zendy; Anna Salvetti | Zendy; Michel Rivoire | Zendy; Amy S. Lee | Zendy; David Durantel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antiviral Activity of PLK1-Targeting siRNA Delivered by Lipid Nanoparticles in HBV-Infected Hepatocytes

Author(s) -

Adrien Foca,

Ammen P. Dhillon,

Thomas Lahlali,

Julie Lucifora,

Anna Salvetti,

Michel Rivoire,

Amy S. Lee,

David Durantel

Publication year - 2019

Publication title -

antiviral therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 87

eISSN - 2040-2058

pISSN - 1359-6535

DOI - 10.3851/imp3361

Subject(s) - cccdna , virology , hbsag , hepatitis b virus , plk1 , viability assay , small interfering rna , biology , microbiology and biotechnology , chemistry , cell , cell culture , transfection , cell cycle , virus , biochemistry , genetics

A link between HBV and PLK1 was clearly evidenced in HBV-driven carcinogenesis, and we have also recently shown that PLK1 is a proviral factor in the early phases of HBV infection. Moreover, we have shown that BI-2536, a small molecule PLK1 inhibitor, was very efficient at inhibiting HBV DNA neosynthesis, notably by affecting nucleocapsid assembly as a result of the modulation of HBc phosphorylation. Yet, as small molecule kinase inhibitors often feature poor selectivity, a more specific and safer strategy to target PLK1 would be needed for a potential development against chronic HBV infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research